[go: up one dir, main page]

WO2018146390A8 - Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer - Google Patents

Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer Download PDF

Info

Publication number
WO2018146390A8
WO2018146390A8 PCT/FR2018/000020 FR2018000020W WO2018146390A8 WO 2018146390 A8 WO2018146390 A8 WO 2018146390A8 FR 2018000020 W FR2018000020 W FR 2018000020W WO 2018146390 A8 WO2018146390 A8 WO 2018146390A8
Authority
WO
WIPO (PCT)
Prior art keywords
compound
diuretics
class
treating cancer
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2018/000020
Other languages
English (en)
Other versions
WO2018146390A1 (fr
Inventor
Laura FONTENILLE
Amel KISSA
Karima Kissa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azelead
Original Assignee
Azelead
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azelead filed Critical Azelead
Priority to US16/484,877 priority Critical patent/US20230137849A1/en
Priority to EP18711384.0A priority patent/EP3579839A1/fr
Publication of WO2018146390A1 publication Critical patent/WO2018146390A1/fr
Publication of WO2018146390A8 publication Critical patent/WO2018146390A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé appartenant à la famille des diurétiques pour traiter le cancer. En particulier, la présente invention concerne un composé pour son utilisation dans le traitement du cancer; ledit composé étant l'althiazide.
PCT/FR2018/000020 2017-02-10 2018-02-09 Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer Ceased WO2018146390A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/484,877 US20230137849A1 (en) 2017-02-10 2018-02-09 Use of a compound of the diuretics class for treating cancer
EP18711384.0A EP3579839A1 (fr) 2017-02-10 2018-02-09 Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR17/51118 2017-02-10
FR1751118A FR3062796B1 (fr) 2017-02-10 2017-02-10 Utilisation d'un compose appartenant a la famillle des diuretiques pour traiter le cancer

Publications (2)

Publication Number Publication Date
WO2018146390A1 WO2018146390A1 (fr) 2018-08-16
WO2018146390A8 true WO2018146390A8 (fr) 2018-10-18

Family

ID=59070772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2018/000020 Ceased WO2018146390A1 (fr) 2017-02-10 2018-02-09 Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer

Country Status (4)

Country Link
US (1) US20230137849A1 (fr)
EP (1) EP3579839A1 (fr)
FR (1) FR3062796B1 (fr)
WO (1) WO2018146390A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230098628A1 (en) * 2021-08-23 2023-03-30 Ckp Therapeutics, Inc. Composition for preventing, alleviating or treating cancer
US11738021B2 (en) 2021-08-23 2023-08-29 Ckp Therapeutics, Inc. Composition and method for preventing, alleviating or treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207648B1 (en) * 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
AU2012211499B2 (en) * 2002-11-26 2014-07-24 Institute Of Virology CA IX-specific inhibitors
US7446357B2 (en) * 2005-05-11 2008-11-04 Micron Technology, Inc. Split trunk pixel layout
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US20120114670A1 (en) * 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
CA2672014A1 (fr) 2009-07-14 2011-01-14 Institut Pasteur Nouvel outil pour etudier les evenements associes a la transition epitheliale-mesenchymale
EP2654776B1 (fr) * 2010-12-21 2018-11-21 Bio-Cancer Treatment International Ltd. Utilisation d'arginase humaine recombinante pégylée pour le traitement d'une leucémie
CN103494822B (zh) * 2013-07-22 2016-06-22 广东工业大学 一种联合他汀类降胆固醇药与噻嗪类抗高血压药物的复方抗癌药物
CN105796570A (zh) * 2016-03-22 2016-07-27 李晨露 一种苄氟噻嗪的药物组合物及其对肝癌的治疗作用

Also Published As

Publication number Publication date
FR3062796A1 (fr) 2018-08-17
US20230137849A1 (en) 2023-05-04
FR3062796B1 (fr) 2019-04-19
EP3579839A1 (fr) 2019-12-18
WO2018146390A1 (fr) 2018-08-16

Similar Documents

Publication Publication Date Title
TN2019000211A1 (en) Antitumoral compounds
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PL3577110T3 (pl) Związki podstawione 8-oksetan-3-ylo-3,8-diazabicyklo[3.2.1]oktan-3-ylem jako inhibitory hiv
HK1254843A1 (en) Compositions comprising bacterial strains
WO2017205459A8 (fr) Composés inhibiteurs de l'egfr
WO2018067512A8 (fr) Composés spirocycliques
WO2018136617A3 (fr) Méthodes de traitement du cancer
WO2016130920A3 (fr) Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
WO2016100652A3 (fr) Procédé pour la préparation d'un composé diarylthiohydantoïne
WO2015142001A3 (fr) Composé doté d'une action cardiotonique et composition pharmaceutique permettant de prévenir ou de traiter l'insuffisance cardiaque et contenant ledit composé
WO2017136450A3 (fr) Composés et méthodes de traitement de maladies médiées par l'arn
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
AU2015352440B2 (en) Compounds
EP4559468A3 (fr) Composés complexes de fer pour une utilisation thérapeutique
HK1252614A1 (zh) 二环化合物
JOP20190190A1 (ar) معالجة سرطان
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
WO2017095950A3 (fr) Composés pour traiter des maladies prolifératives
WO2018146390A8 (fr) Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer
WO2018211323A8 (fr) Composés hétérocycliques pour traiter une maladie
WO2018211324A8 (fr) Promédicaments pour traiter une maladie
IL282692A (en) Compounds derived from madrasin, a preparation and their uses for the treatment of cancer
WO2018058144A8 (fr) Activateur de ship1 pour le traitement de la prostatite
WO2016086022A3 (fr) Composés imidazolyle hétéroaromatiques et méthodes de traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18711384

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018711384

Country of ref document: EP

Effective date: 20190910

WWW Wipo information: withdrawn in national office

Ref document number: 2018711384

Country of ref document: EP